Open Access

Empagliflozin across the spectrum of ejection fraction in HF ‒ aggregate findings from the EMPEROR programme

Event: ESC Congress 2021 - The Digital Experience
Topic: Chronic Heart Failure
Session type: Satellite Symposium
Organised by Charité Friends & Sponsors Trust supported by an unrestricted educational grant from The Boehringer Ingelheim & Eli Lilly and Company Alliance
Date: 29 August 2021
Time: 11:30 - 12:00

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

4 presentations in this session

Introduction.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Thumbnail

EMPEROR-Preserved: main results.

Speaker: Professor S. Anker (Berlin, DE)
Thumbnail

EMPEROR-Reduced and EMPEROR-Preserved: patient-level pooled analysis.

Speaker: Doctor M. Packer (Dallas, US)
Thumbnail

Panel discussion.

Thumbnail

3 speakers from this session

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)
70 presentations
1 follower

Professor Stefan Anker

Charite Universitatsmedizin Berlin, Berlin (Germany)
116 presentations
4 followers

Doctor Milton Packer

Baylor University Medical Center, Dallas (United States of America)
33 presentations
3 followers

Related content

ESC Premium Access

Trials Focus: GUIDE-HF / EMPEROR-Preserved

3 December 2021

ESC Premium Access

Update on endocarditis in 2021

3 December 2021

ESC Premium Access

Pregnancy in women with cardiovascular disease

3 December 2021

This platform is supported by

logo Novo Nordisk